Company profile: NeuroOne Medical Technologies
1.1 - Company Overview
Company description
- Provider of neurosurgical technologies, including the OneRF Radiofrequency Ablation System for bedside monitoring, mapping, and ablation to create radiofrequency lesions in nervous tissue for epilepsy treatment; the Evo sEEG Electrode for recording brain activity and identifying seizure foci for epilepsy treatment; and the Evo Cortical Electrode for ECoG/iEEG surgeries to monitor, record, and stimulate the brain surface for less than 30 days.
Products and services
- Evo® Cortical Electrode: Intracranial electrodes used in ECoG/iEEG surgeries to monitor, record, and stimulate the brain surface for less than 30 days, supporting surgical care for neurological disorders
- Evo® sEEG Electrode: Stereoelectroencephalography (sEEG) electrodes that record brain activity and aid identification of seizure foci zones for epilepsy treatment to guide surgical care
- OneRF™ Radiofrequency Ablation System: Radiofrequency system that creates lesions in nervous tissue during functional neurosurgical procedures, delivering bedside monitoring, mapping, and ablation for epilepsy treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuroOne Medical Technologies
Alkahest
HQ: United States
Website
- Description: Provider of blood-derived therapies for neurological diseases focused on age-related cognitive decline. Offers AKST4290, an orally administered drug targeting CCR3 for wet AMD and Parkinson's; GRF6019 and GRF6021, selected human plasma fractions for Alzheimer's and Parkinson's with cognitive impairment; AKST1210 to remove beta-2 microglobulin and improve cognitive impairment in end-stage renal disease; and novel plasma proteome factor candidates. Collaborates with Grifols.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alkahest company profile →
IntraBio
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and candidates, including IB1001 (orally administered N-Acetyl-Leucine) for rare neurological disorders such as NPC, GM1/GM2 gangliosidosis and inherited cerebellar ataxias; IB2000 and IB5000 for Ménière’s disease with clinical efficacy and safety in observational studies; IB3000 (NAADP analogues/agonists) with pre-clinical potential for Type 2 Diabetes, autism and neurodegenerative disorders; IB4000 (UDCA) for NPC liver dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntraBio company profile →
Scienture
HQ: United States
Website
- Description: Provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scienture company profile →
Cerus Endovascular
HQ: United Kingdom
Website
- Description: Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus Endovascular company profile →
GH Research
HQ: Ireland
Website
- Description: Provider of clinical-stage 5-MeO-DMT (mebufotenin) therapies for psychiatric and neurological disorders, initially focused on treatment-resistant depression: GH001 inhalation (Phase 2b TRD; Phase 2a bipolar II and postpartum depression), GH002 intravenous (completed Phase 1), and GH003 intranasal (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GH Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuroOne Medical Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuroOne Medical Technologies
2.2 - Growth funds investing in similar companies to NeuroOne Medical Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuroOne Medical Technologies
4.2 - Public trading comparable groups for NeuroOne Medical Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →